Witzig T - Search Results

1

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM. Mir MA, et al. Among authors: witzig t. Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24. Blood. 2015. PMID: 25422100 Free PMC article.

2

Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section method.

Witzig TE, Banks PM, Stenson MJ, Griepp PR, Katzmann JA, Habermann TM, Colgan JP, Gonchoroff NJ. Witzig TE, et al. Am J Clin Pathol. 1990 Sep;94(3):280-6. doi: 10.1093/ajcp/94.3.280. Am J Clin Pathol. 1990. PMID: 2204263

3

Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure.

Witzig TE, Gonchoroff NJ, Greipp PR, Katzmann JA, Stenson MJ, Habermann TM, Colgan JP, Therneau TM, Banks PM. Witzig TE, et al. Am J Clin Pathol. 1989 Mar;91(3):298-301. doi: 10.1093/ajcp/91.3.298. Am J Clin Pathol. 1989. PMID: 2646907

4

Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies.

Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA. Greipp PR, et al. Among authors: witzig te. Mayo Clin Proc. 1987 Nov;62(11):969-77. doi: 10.1016/s0025-6196(12)65066-6. Mayo Clin Proc. 1987. PMID: 3118117

5

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.

Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Greipp PR, et al. Among authors: witzig te. Blood. 1993 Jun 15;81(12):3382-7. Blood. 1993. PMID: 8507875 Free article.

6

S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma.

Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR. Witzig TE, et al. Cancer. 1995 Sep 15;76(6):1059-64. doi: 10.1002/1097-0142(19950915)76:6<1059::aid-cncr2820760621>3.0.co;2-e. Cancer. 1995. PMID: 8625208

7

Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.

Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Witzig TE, et al. Blood. 1996 Sep 1;88(5):1780-7. Blood. 1996. PMID: 8781435 Free article.

8

Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.

Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG. Hartmann LC, et al. Among authors: witzig te. N Engl J Med. 1997 Jun 19;336(25):1776-80. doi: 10.1056/NEJM199706193362502. N Engl J Med. 1997. PMID: 9187067 Free article. Clinical Trial.

9

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. Among authors: witzig te. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

10

A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.

Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM. Witzig TE, et al. Leuk Lymphoma. 1998 Jan;28(3-4):307-14. doi: 10.3109/10428199809092686. Leuk Lymphoma. 1998. PMID: 9517502 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

643 results

Search Page

Filters